Epitome Pharmaceuticals identifies, develops and licenses promising medications. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data.
Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
Twin Sample™ Biopsy Needle (Now available)
The Twin Sample biopsy needle was invented to address the need for fresh tissue for molecular assays. The needle harvests paired samples with minimal intrusion, one for the pathology and the other for your lab.Cold Sore Prevention
On October 26, 2011 the US patent office allowed the Epitome Pharmaceuticals patent for a lip balm formulation containing 1% Vitamin C and 2% green tea extract, as well as an enhancer for absorption.Early Drug Development in Cooperation with the Pharmaceutical Industry
Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data. Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.